Lisocabtagene maraleucel

From WikiMD.org
Jump to navigation Jump to search

Lisocabtagene Maraleucel

Lisocabtagene Maraleucel (pronounced as li-so-kab-TA-jeen mar-a-LOO-sel) is a type of immunotherapy used in the treatment of certain types of B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). It is a chimeric antigen receptor (CAR) T-cell therapy, which involves modifying a patient's own T cells to fight cancer cells.

Etymology

The name Lisocabtagene Maraleucel is derived from the following components: 'Liso-' is a prefix used in pharmacology to denote a product of Bristol-Myers Squibb, the company that developed the drug. 'cabtagene' refers to the CAR T-cell gene modification, and 'maraleucel' indicates that the drug targets the CD19 antigen on B cells ('mara-' from the Latin 'mare' meaning 'sea', metaphorically representing the B-cell surface, and '-leucel' from 'leukocyte', a type of white blood cell).

Usage

Lisocabtagene Maraleucel is used for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and FL grade 3B.

Mechanism of Action

Lisocabtagene Maraleucel works by modifying the patient's T cells to express a chimeric antigen receptor that targets the CD19 antigen, a protein on the surface of B cells. This allows the T cells to recognize and kill the B cells, which are often cancerous in patients with B-cell lymphoma.

Related Terms

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski